Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab

Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder managed with plasma exchange (PLEX) and steroids. Addition of rituximab (RTX) to initial disease treatment has been shown to lower future relapse rates. Information as to whether upfront cyclophosphami...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Med (Lausanne)
Egile Nagusiak: Abou-Ismail, Mouhamed Yazan, Arafah, Yasmin, Fu, Pingfu, Cao, Shufen, Schmaier, Alvin H., Nayak, Lalitha
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2020
Gaiak:
Medicine
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657267/
https://ncbi.nlm.nih.gov/pubmed/33195351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2020.588526
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak